Should non-culprit lesions be revascularized in STEMI and NSTEMI? Should revascularization of non-culprit lesions occur in a simultaneous or staged manner? How do these recommendations differ when acute MI presents with cardiogenic shock? When DAPT is reduced to SAPT, which P2Y12 inhibitor is favored for monotherapy? When is de-escalation from ticagrelor/prasugrel to clopidogrel reasonable? In post-PCI patients requiring antithrombotic therapy, what should the duration of triple therapy be, and what is the P2Y12 inhibitor of choice? What is the role of Impella, IABP, and VA-ECMO in ACS with cardiogenic shock? Tune in for answers to these questions in this "deep dive" of the 2025 AHA/ACC Guideline for the Management of Patients with Acute Coronary Syndromes.

Bonus – Accompanying YouTube Talk: https://www.youtube.com/watch?v=MccydgyxK_I

Difficulty Level: Intermediate

You are listening to Hu Said: Guideline Lifeline

Please subscribe, rate, and support the channel! Ads help keep materials free for everyone.

More MedEd resources available at ⁠⁠www.rueyhu.com⁠⁠

Updates at Twitter/X: ⁠⁠@Ruey_Hu⁠